← Back to Search

secukinumab 1 for Hidradenitis Suppurativa (SUNSHINE Trial)

Phase 3
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of HS ≥ 1 year prior to baseline.
Written informed consent must be obtained before any assessment is performed.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

SUNSHINE Trial Summary

This study is evaluating whether a medication may help treat hidradenitis suppurativa.

Eligible Conditions
  • Hidradenitis Suppurativa

SUNSHINE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SUNSHINE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hidradenitis
Secondary outcome measures
Participants achieving NRS30
Percentage change in AN count
Proportion of patients with Hidradenitis Suppurativa (HS) flares

SUNSHINE Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: secukinumab 1Active Control1 Intervention
Secukinumab 300mg every 2 weeks
Group II: secukinumab 2Active Control1 Intervention
Secukinumab 300mg every 4 weeks
Group III: placebo 1Placebo Group1 Intervention
Placebo group to secukinumab 300mg every 2 weeks
Group IV: placebo 2Placebo Group1 Intervention
Placebo group to secukinumab 300mg every 4 weeks

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,855 Previous Clinical Trials
4,196,808 Total Patients Enrolled
6 Trials studying Hidradenitis Suppurativa
2,159 Patients Enrolled for Hidradenitis Suppurativa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
2019. "This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03713619.
~88 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top